Published in J Infect Dis on February 15, 2008
Immunosenescence: what does it mean to health outcomes in older adults? Curr Opin Immunol (2009) 2.09
Does Influenza Vaccination Modify Influenza Severity? Data on Older Adults Hospitalized With Influenza During the 2012-2013 Season in the United States. J Infect Dis (2015) 2.04
Vaccination in the elderly: an immunological perspective. Trends Immunol (2009) 1.60
Influenza vaccine responses in older adults. Ageing Res Rev (2010) 1.35
Seasonal influenza vaccine and protection against pandemic (H1N1) 2009-associated illness among US military personnel. PLoS One (2010) 1.32
Long-Lived Plasma Cells Are Contained within the CD19(-)CD38(hi)CD138(+) Subset in Human Bone Marrow. Immunity (2015) 1.27
Youth-specific considerations in the development of preexposure prophylaxis, microbicide, and vaccine research trials. J Acquir Immune Defic Syndr (2010) 1.24
Prevalence of seroprotection against the pandemic (H1N1) virus after the 2009 pandemic. CMAJ (2010) 1.18
Unique biomarkers for B-cell function predict the serum response to pandemic H1N1 influenza vaccine. Int Immunol (2012) 1.14
AID activity in B cells strongly correlates with polyclonal antibody affinity maturation in-vivo following pandemic 2009-H1N1 vaccination in humans. PLoS Pathog (2012) 1.07
Impaired antibody response to influenza vaccine in HIV-infected and uninfected aging women is associated with immune activation and inflammation. PLoS One (2013) 1.06
Durability of antibody responses after receipt of the monovalent 2009 pandemic influenza A (H1N1) vaccine among HIV-infected and HIV-uninfected adults. Vaccine (2011) 1.04
Effectiveness of influenza vaccine in aging and older adults: comprehensive analysis of the evidence. Clin Interv Aging (2012) 1.04
Young and elderly patients with type 2 diabetes have optimal B cell responses to the seasonal influenza vaccine. Vaccine (2013) 1.03
Pneumonia immunization in older adults: review of vaccine effectiveness and strategies. Clin Interv Aging (2012) 0.90
Safety, immunogenicity, and tolerability of three influenza vaccines in older adults: results of a randomized, controlled comparison. Hum Vaccin Immunother (2013) 0.89
Quantifying Protection Against Influenza Virus Infection Measured by Hemagglutination-inhibition Assays in Vaccine Trials. Epidemiology (2016) 0.88
Quantifying the economic value and quality of life impact of earlier influenza vaccination. Med Care (2015) 0.87
Persistence of Antibodies to Influenza Hemagglutinin and Neuraminidase Following One or Two Years of Influenza Vaccination. J Infect Dis (2015) 0.86
Immune senescence in old and very old rhesus monkeys: reduced antibody response to influenza vaccination. Age (Dordr) (2012) 0.86
Good and bad memories following rituximab therapy. Arthritis Rheum (2010) 0.85
Randomized, controlled trial of high-dose influenza vaccine among frail residents of long-term care facilities. J Infect Dis (2014) 0.85
Vaccinology in the third millennium: scientific and social challenges. Curr Opin Virol (2016) 0.84
Profiles of influenza A/H1N1 vaccine response using hemagglutination-inhibition titers. Hum Vaccin Immunother (2015) 0.83
Effectiveness of influenza vaccine against laboratory-confirmed influenza, in the late 2011-2012 season in Spain, among population targeted for vaccination. BMC Infect Dis (2013) 0.83
The cost-effectiveness and value of information of three influenza vaccination dosing strategies for individuals with human immunodeficiency virus. PLoS One (2011) 0.81
Double dose vs. standard dose influenza vaccination in patients with heart failure: a pilot study. Eur J Heart Fail (2013) 0.80
A critical review of perfluorooctanoate and perfluorooctanesulfonate exposure and immunological health conditions in humans. Crit Rev Toxicol (2016) 0.79
Lack of persistence of influenza vaccine antibody titers in patients with heart failure. J Card Fail (2013) 0.79
The generation of memory B cells is maintained, but the antibody response is not, in the elderly after repeated influenza immunizations. Vaccine (2016) 0.78
AID in aging and autoimmune diseases. Autoimmunity (2013) 0.76
Persistence of influenza vaccine-induced antibody in lung transplant patients and healthy individuals beyond the season. Hum Vaccin Immunother (2012) 0.76
Impact of anti-rheumatic treatment on immunogenicity of pandemic H1N1 influenza vaccine in patients with arthritis. Arthritis Res Ther (2014) 0.76
Influenza vaccination of pregnant women protects them over two consecutive influenza seasons in a randomized controlled trial. Expert Rev Vaccines (2016) 0.75
Cytomegalovirus serostatus, inflammation, and antibody response to influenza vaccination in older adults: The moderating effect of beta blockade. Brain Behav Immun (2016) 0.75
Changes of immunogenic profiles between a single dose and one booster influenza vaccination in hemodialysis patients - an 18-week, open-label trial. Sci Rep (2016) 0.75
Influenza vaccine immunogenicity in patients with primary central nervous system malignancy. Neuro Oncol (2014) 0.75
Metformin improves in vivo and in vitro B cell function in individuals with obesity and Type-2 Diabetes. Vaccine (2017) 0.75
Human metapneumovirus infections in hospitalized children. Emerg Infect Dis (2003) 3.99
Association between the 2008-09 seasonal influenza vaccine and pandemic H1N1 illness during Spring-Summer 2009: four observational studies from Canada. PLoS Med (2010) 3.85
Methodologic issues regarding the use of three observational study designs to assess influenza vaccine effectiveness. Int J Epidemiol (2007) 3.33
Novel avian influenza H7N3 strain outbreak, British Columbia. Emerg Infect Dis (2004) 2.90
An outbreak of severe respiratory tract infection due to human metapneumovirus in a long-term care facility. Clin Infect Dis (2007) 2.63
Component-specific effectiveness of trivalent influenza vaccine as monitored through a sentinel surveillance network in Canada, 2006-2007. J Infect Dis (2009) 2.59
The changing age and seasonal profile of pertussis in Canada. J Infect Dis (2002) 2.53
Effectiveness of AS03 adjuvanted pandemic H1N1 vaccine: case-control evaluation based on sentinel surveillance system in Canada, autumn 2009. BMJ (2011) 2.50
Household transmission of the 2009 pandemic A/H1N1 influenza virus: elevated laboratory‐confirmed secondary attack rates and evidence of asymptomatic infections. Clin Infect Dis (2010) 2.41
The number needed to vaccinate to prevent infant pertussis hospitalization and death through parent cocoon immunization. Clin Infect Dis (2011) 1.94
Multiplex real-time PCR assay for detection of influenza and human respiratory syncytial viruses. J Clin Microbiol (2004) 1.64
Immuno-epidemiologic correlates of pandemic H1N1 surveillance observations: higher antibody and lower cell-mediated immune responses with advanced age. J Infect Dis (2011) 1.61
A sentinel platform to evaluate influenza vaccine effectiveness and new variant circulation, Canada 2010-2011 season. Clin Infect Dis (2012) 1.58
Measles elimination in Canada. J Infect Dis (2004) 1.51
Cross-reactive and vaccine-induced antibody to an emerging swine-origin variant of influenza A virus subtype H3N2 (H3N2v). J Infect Dis (2012) 1.47
Protective measures and human antibody response during an avian influenza H7N3 outbreak in poultry in British Columbia, Canada. CMAJ (2007) 1.43
Seasonal influenza vaccine and increased risk of pandemic A/H1N1‐related illness: first detection of the association in British Columbia, Canada. Clin Infect Dis (2010) 1.43
Analysis of mortality following a mass immunization campaign with serogroup C meningococcal conjugate vaccine: methodological difficulties and imperfect solutions. Vaccine (2009) 1.42
Pertussis resurgence in Canada largely caused by a cohort effect. Pediatr Infect Dis J (2003) 1.39
Comparison of automated microarray detection with real-time PCR assays for detection of respiratory viruses in specimens obtained from children. J Clin Microbiol (2009) 1.35
Risk of Guillain-Barré syndrome following H1N1 influenza vaccination in Quebec. JAMA (2012) 1.25
Risk factors for hospitalization and severe outcomes of 2009 pandemic H1N1 influenza in Quebec, Canada. Influenza Other Respir Viruses (2011) 1.24
Influenza A/subtype and B/lineage effectiveness estimates for the 2011-2012 trivalent vaccine: cross-season and cross-lineage protection with unchanged vaccine. J Infect Dis (2014) 1.23
Comparison of risk factors for human metapneumovirus and respiratory syncytial virus disease severity in young children. J Infect Dis (2012) 1.21
Effectiveness of pneumococcal conjugate vaccine using a 2+1 infant schedule in Quebec, Canada. Pediatr Infect Dis J (2010) 1.19
Prevalence of seroprotection against the pandemic (H1N1) virus after the 2009 pandemic. CMAJ (2010) 1.18
Estimates of influenza vaccine effectiveness for 2007-2008 from Canada's sentinel surveillance system: cross-protection against major and minor variants. J Infect Dis (2012) 1.14
Evaluation of serological diagnostic methods for the 2009 pandemic influenza A (H1N1) virus. Clin Vaccine Immunol (2011) 1.14
Safe vaccination of patients with egg allergy with an adjuvanted pandemic H1N1 vaccine. J Allergy Clin Immunol (2010) 1.13
The need for validation of statistical methods for estimating respiratory virus-attributable hospitalization. Am J Epidemiol (2009) 1.13
Randomized controlled trial of dose response to influenza vaccine in children aged 6 to 23 months. Pediatrics (2011) 1.12
Antibody persistence and response to 2010-2011 trivalent influenza vaccine one year after a single dose of 2009 AS03-adjuvanted pandemic H1N1 vaccine in children. Vaccine (2011) 1.11
Human illness and isolation of low-pathogenicity avian influenza virus of the H7N3 subtype in British Columbia, Canada. J Infect Dis (2006) 1.10
Egg-allergic patients can be safely vaccinated against influenza. J Allergy Clin Immunol (2012) 1.09
Antibody persistence and the effect of a booster dose given 5, 10 or 15 years after vaccinating preadolescents with a recombinant hepatitis B vaccine. Vaccine (2012) 1.08
Distribution and clinical impact of human respiratory syncytial virus genotypes in hospitalized children over 2 winter seasons. J Infect Dis (2005) 1.06
Coordinated response to SARS, Vancouver, Canada. Emerg Infect Dis (2006) 1.04
Modeling the impact of one- and two-dose varicella vaccination on the epidemiology of varicella and zoster. Vaccine (2010) 1.03
Comparative long term immunogenicity of two recombinant hepatitis B vaccines and the effect of a booster dose given after five years in a low endemicity country. Pediatr Infect Dis J (2005) 1.03
Impact of the quebec school-based hepatitis B immunization program and potential benefit of the addition of an infant immunization program. Pediatr Infect Dis J (2006) 1.03
Oculo-respiratory syndrome: a new influenza vaccine-associated adverse event? Clin Infect Dis (2003) 1.02
Effectiveness of a mass immunization campaign using serogroup C meningococcal conjugate vaccine. JAMA (2004) 1.01
Influenza Β/Victoria antigen induces strong recall of Β/Yamagata but lower Β/Victoria response in children primed with two doses of Β/Yamagata. Pediatr Infect Dis J (2011) 1.00
Assessment of the status of measles elimination from reported outbreaks: United States, 1997-1999. J Infect Dis (2004) 0.98
Effectiveness of serogroup C meningococcal conjugate vaccine: a 7-year follow-up in Quebec, Canada. Pediatr Infect Dis J (2011) 0.98
Risk factors for influenza among health care workers during 2009 pandemic, Toronto, Ontario, Canada. Emerg Infect Dis (2013) 0.98
Interim estimates of 2015/16 vaccine effectiveness against influenza A(H1N1)pdm09, Canada, February 2016. Euro Surveill (2016) 0.98
Seroprevalence of hepatitis A infection in a low endemicity country: a systematic review. BMC Infect Dis (2005) 0.98
Strain variation among Bordetella pertussis isolates from Québec and Alberta provinces of Canada from 1985 to 1994. J Clin Microbiol (2003) 0.97
Field performance of a rapid diagnostic test for influenza in an ambulatory setting. J Clin Microbiol (2009) 0.96
[Why are some children incompletely vaccinated at the age of 2?]. Can J Public Health (2003) 0.95
The effect of changing from whole-cell to acellular pertussis vaccine on the epidemiology of hospitalized children with pertussis in Canada. Pediatr Infect Dis J (2007) 0.94
School absenteeism as an adjunct surveillance indicator: experience during the second wave of the 2009 H1N1 pandemic in Quebec, Canada. PLoS One (2012) 0.94
Seasonal vaccine effectiveness against pandemic A/H1N1. Lancet (2010) 0.93
Aggregate content influences the Th1/Th2 immune response to influenza vaccine: evidence from a mouse model. J Med Virol (2004) 0.93
Host and viral factors affecting clinical performance of a rapid diagnostic test for respiratory syncytial virus in hospitalized children. J Pediatr (2013) 0.92
Varicella vaccine: factors influencing uptake. Can J Public Health (2003) 0.92
Cross-lineage influenza B and heterologous influenza A antibody responses in vaccinated mice: immunologic interactions and B/Yamagata dominance. PLoS One (2012) 0.92
Comparison of pandemic and seasonal influenza in the pediatric emergency department. Pediatr Infect Dis J (2011) 0.92
Nationwide canadian study of hepatitis a antibody prevalence among children eight to thirteen years old. Pediatr Infect Dis J (2005) 0.92
A review of interventions triggered by hepatitis A infected food-handlers in Canada. BMC Health Serv Res (2006) 0.91
Is routine influenza immunization warranted in early pregnancy? Vaccine (2009) 0.91
Long-lasting measles outbreak affecting several unrelated networks of unvaccinated persons. J Infect Dis (2009) 0.91
Human respiratory syncytial virus and other viral infections in infants receiving palivizumab. J Clin Virol (2008) 0.90
Seasonal vaccine and H1N1. Selection bias explains seasonal vaccine's protection. BMJ (2009) 0.90
Hospitalizations for diarrhea in Quebec children from 1985 to 1998: estimates of rotavirus-associated diarrhea. Can J Infect Dis (2002) 0.89
Potential cost-effectiveness of annual influenza immunization for infants and toddlers: experience from Canada. Vaccine (2006) 0.89
Mutations acquired during cell culture isolation may affect antigenic characterisation of influenza A(H3N2) clade 3C.2a viruses. Euro Surveill (2016) 0.88
Influenza vaccine effectiveness in the elderly based on administrative databases: change in immunization habit as a marker for bias. PLoS One (2011) 0.88
Transmission of acute gastroenteritis and respiratory illness from children to parents. Pediatr Infect Dis J (2014) 0.88
Effectiveness of pandemic H1N1 vaccine against influenza-related hospitalization in children. Pediatrics (2011) 0.87
Effectiveness of serogroup C meningococcal polysaccharide vaccine: results from a case-control study in Quebec. Clin Infect Dis (2005) 0.87
Understanding suboptimal influenza vaccine effectiveness within the agent, host, and environment paradigm. Clin Infect Dis (2013) 0.86
Antibiotic use in children is not influenced by the result of rapid antigen detection test for the respiratory syncytial virus. J Clin Virol (2007) 0.85
Infections by human coronavirus-NL in hospitalized children. Pediatr Infect Dis J (2005) 0.85
Trends of hepatitis A hospitalization and risk factors in Quebec, Canada, between 1990 and 2003. BMC Infect Dis (2007) 0.85
Skin testing to evaluate oculo-respiratory syndrome (ORS) associated with influenza vaccination during the 2000-2001 season. Vaccine (2002) 0.85
Re: "effectiveness of adjuvanted influenza vaccination in elderly subjects in northern Italy". Am J Epidemiol (2013) 0.85
Long-term persistence of immunity after vaccination of pre-adolescents with low doses of a recombinant hepatitis B vaccine. Hum Vaccin Immunother (2013) 0.85
Antibody and immune memory persistence after vaccination of preadolescents with low doses of recombinant hepatitis B vaccine. Hum Vaccin (2010) 0.83
Adverse events associated with 2010 CSL and other inactivated influenza vaccines. Med J Aust (2011) 0.83
Serial vaccination and the antigenic distance hypothesis: effects on influenza vaccine effectiveness during A(H3N2) epidemics in Canada, 2010-11 to 2014-15. J Infect Dis (2017) 0.82
Genetic diversity and molecular evolution of the major human metapneumovirus surface glycoproteins over a decade. J Clin Virol (2013) 0.82
The cost of preventing rabies at any cost: post-exposure prophylaxis for occult bat contact. Vaccine (2008) 0.82
Antibody kinetics among 8-10 years old respondents to hepatitis B vaccination in a low endemic country and the effect of a booster dose given 5 or 10 years later. Vaccine (2009) 0.81
Immunogenicity of quadrivalent HPV and combined hepatitis A and B vaccine when co-administered or administered one month apart to 9-10 year-old girls according to 0-6 month schedule. Hum Vaccin Immunother (2014) 0.81
Evaluation of meningococcal serogroup C conjugate vaccine programs in Canadian children: interim analysis. Vaccine (2012) 0.80
Pneumococcal vaccination and myocardial infarction. CMAJ (2009) 0.79
Does antigen-specific cytokine response correlate with the experience of oculorespiratory syndrome after influenza vaccine? J Infect Dis (2003) 0.79
Increased risk of anaphylaxis following administration of 2009 AS03-adjuvanted monovalent pandemic A/H1N1 (H1N1pdm09) vaccine. Vaccine (2013) 0.79
Systematic community- and hospital-based surveillance for enterovirus-D68 in three Canadian provinces, August to December 2014. Euro Surveill (2015) 0.79
Measles in children vaccinated with 2 doses of MMR. Pediatrics (2013) 0.78
Mechanism for Seasonal Vaccine Effect on Pandemic H1N1 Risk Remains Uncertain. Clin Infect Dis (2011) 0.78
Transmission dynamics and risk factors for pandemic H1N1-related illness: outbreak investigation in a rural community of British Columbia, Canada. Influenza Other Respir Viruses (2012) 0.78
Immunogenicity of two paediatric doses of monovalent hepatitis B or combined hepatitis A and B vaccine in 8-10-year-old children. Vaccine (2004) 0.78
Molecular evolution of respiratory syncytial virus fusion gene, Canada, 2006-2010. Emerg Infect Dis (2012) 0.78
Seroconversion to seasonal influenza viruses after A(H1N1)pdm09 virus infection, Quebec, Canada. Emerg Infect Dis (2012) 0.77
Economic evaluation of an extended acellular pertussis vaccine program for adolescents in Québec, Canada. Paediatr Drugs (2005) 0.77
A nationwide survey of past hepatitis A infections among Canadian adults. Vaccine (2010) 0.77
Has the change to acellular pertussis vaccine improved or worsened pertussis control? CMAJ (2006) 0.77